Fig 8.

iNOS plays a role in the suppressive mechanism of LP-BM5-induced Ly6G⁺-depleted CD11b⁺-enriched B6 splenocytes (according to [³H]thymidine incorporation suppression assays). (A) A dose-dependent titration curve for the ability of the NOS inhibitor l-NMMA or control d-NMMA to inhibit suppression of LPS or α-CD40- and IL-4-dependent proliferation by Ly6G⁺-depleted CD11b⁺-enriched suppressor cells. The presented pattern of results is representative of one additional dose response experiment for each type of B-cell stimulation. (B) The means ± SD for the percentage of blockade by 0.5 to 1 mM l-NMMA (versus d-NMMA) of the percentage of inhibition of the control proliferative response for 4 experiments, all of which utilized Ly6G⁺-depleted CD11b⁺-enriched splenocytes as suppressor cells. (C) The suppressive capability of LP-BM5-infected iNOS^−/− Ly6G⁺-depleted CD11b⁺-enriched splenocytes is compared to that of w.t. mouse splenocytes. This pattern of results is representative of three additional experiments. Significance levels: *, P < 0.05; **, P < 0.01; and ***, P < 0.001.